Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a rare but potentially life threatening adverse drug reaction. DILI may mimic any morphologic characteristic of acute or chronic liver disease, and the histopathologic features of DILI may be indistinguishable from those of other causes of liver injury, such as acute viral hepatitis. In this review article, we provide an update on causative agents, clinical features, pathogenesis, diagnosis modalities, and outcomes of DILI. In addition, we review results of recently reported genetic studies and updates on pharmacological and invasive treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Various host genetic factors related to drug‐metabolizing enzymes and transporters have been reported as increasing DILI susceptibility56 (Table 3).”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · Gastroenterology Research · doi:10.1053/j · Cited by 2,759
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Early indicators of prognosis in fulminant hepatic failure
O'Grady, J. G., Alexander, G. J. M., Hayllar, K. M., & Williams, R. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90081-4 · Cited by 2,085
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149 · cited 1×
“However, early in the course of livery injury, these miRNAs are elevated.(87) In addition, they appear to have a prognostic role when considering liver transplant in acetaminophen hepatotoxicity.”
BackgroundCriteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106 · cited 1×
“The clinical spectrum of liver injury in DILI is classified according to the Council for International Organizations of Medical Sciences (CIOMS).(58) Hepatocellular DILI is established once there is an isolated elevation of alanine aminotransferase (ALT) greater than two times the upper limit of normal, or when the ra…”
BackgroundACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348 · cited 1×
“Another polymorphic isoform of UGT, UGTB7, is associated with DILI induced by diclofenac by increasing glucuronidation activity.(31) Mutations in GST mu 1 (GSTM1) and GST theta 1 (GSTT1), other hepatocyte enzymes involved in metabolism and detoxification, may lead to partial deletion, absence of enzymatic activity, an…”
BackgroundAndrade, R. J., Lucena, I. M., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., García-Cortés, M., Fernández, C. M., Pelaez, G., Rodrigo, L., et al. (2006) · Hepatology · doi:10.1002/hep.21424 · Cited by 309 · cited 2×
“Although most of the patients recover from DILI, there are patients who develop chronic liver disease, with the incidence of developing chronic DILI in one Spanish registry reported to be 6%.(113) Patients who fulfill Hy’s Law and patients with a predominant cholestatic type of DILI have a worse prognosis and increase…”
BackgroundResult
Cited by
Cellular and molecular mechanisms of curcumin in prevention and treatment of disease
Patel, S. S., Acharya, A., Ray, R. S., Agrawal, R., Raghuwanshi, R., & Jain, P. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1552244 · Cited by 511
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
“[55] (iv) Host genetic risk factors: Various host genetic factors related to drug‐metabolizing enzymes and transporters have been reported as increasing DILI susceptibility[56] (Table 3).”
BackgroundTeschke, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00730 · Cited by 62
Metadata
- Venue
- Journal of Clinical and Translational Hepatology
- Publisher
- Xia & He Publishing
- Published
- 2015-06-15
- Volume
- 3
- Issue
- 2
- Pages
- 99-108
- ISSN
- 2225-0719
- 2310-8819
- Cited by
- 55
- References
- 13
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.